Obesity and Cardio-Vascular Diseases.pptx

Obesity is the latest pandemic engulfing the whole world. Here we present the relationship of obesity and cardiovascular diseases.

1. OBESITY AND CVD

2. The Epidemiological Link Between Diabetes, Obesity and CVD

3. The Epidemiological Link Between Diabetes, Obesity and CVD (cont)

4. Multiple Mechanisms Link Obesity With CVD

5. CV Risk Mitigation With Bariatric Surgery The Swedish Obesity Subjects Study

6. Cardiovascular Outcomes With Bariatric Surgery Findings From the SOS Study

7. Obesity and Cardiovascular Disease The Effect of Bariatric Surgery

8. Intensive Lifestyle Intervention in People Living With Overweight or Obesity and T2D in the Look AHEAD Study

9. Look AHEAD Post Hoc Analysis

10. How Much Weight Loss Is Needed to Improve Cardiometabolic Health?

11. CVOT Results With GLP-1 RAs in T2D

12. CVOTs of Antiobesity Drugs

13. Weight Loss With GLP-1 RAs Body Weight Change in the STEP 5 Trial

14. Targeting GLP-1 Impacts Multiple Biological Processes

15. Summary

16. CV EVENT REDN.IN OVERWEIGHT AND OBESE

17. Obesity Is Linked to Cardiovascular Risk

18. GLP-1 RA Efficacy for CV Outcomes Meta-Analysis in T2D

19. Newer Agents Available for Treatment of Obesity

20. Newer Agents Available for Treatment of Obesity

21. SELECT Trial GLP-1 RA for CV Risk Reduction in Obesity

22. SELECT Trial Baseline Characteristics

23. SELECT Trial Results CV Efficacy

24. SELECT Trial Results CV Efficacy

25. SELECT Trial Results Prespecified Subgroup Analyses for Primary Efficacy Endpoint

26. Results Cardiovascular Outcomes

27. SELECT Trial Metabolic Outcomes

28. SELECT Trial Safety and Adverse Events

29. SELECT Trial Summary and Interpretations

30. SURMOUNT-1 Tirzepatide in People With Overweight or Obesity

31. SURMOUNT-1 Weight Loss + Improvements in Cardiometabolic Risk Factors

32. METABOLIC OUTCOME IN OBESE

33. Obesity Is a Risk Factor for CVD

34. Overweight or Obesity Increases the Risk of CHD Even in the Absence of Metabolic Abnormalities

35. Intentional Weight Loss Associated With Lower Mortality in People With Diabetes

36. GLP-1 Receptor Agonists

37. Effects of GLP-1 RAs on CV Risk Factors

38. GLP-1-RAs Showing CV Benefit in CVOTs 3-Point MACE

39. Tirzepatide Dual GIP Receptor and GLP-1 Receptor Agonist

40. SURMOUNT-1 Tirzepatide for the Treatment of Obesity

41. SURMOUNT-1 Weight Loss Improved Cardiometabolic Risk Factors in Patients With Obesity

42. SURMOUNT-1 Weight Loss Improved Cardiometabolic Risk Factors in Patients With Obesity

43. SELECT Trial

44. Cardiovascular-Kidney-Metabolic (CKM) Syndrome

45. Stages of CKM Syndrome

46. SELECT Trial Effect of Semaglutide vs Placebo on Body Weight

47. SELECT Trial Effect of Semaglutide vs Placebo on Waist Circumference

48. SELECT Trial Effect of Semaglutide vs Placebo on HbA 1c

49. SELECT Trial Semaglutide Improved Traditional CV Risk Factors at Week 104

50. SELECT Trial Secondary Endpoint: Time-to-Event Nephropathy

51. Conclusions

52. OBESITY CARE IN CARDIOLOGY

53. Introduction

54. Indications for GLP-1 RAs/GLP-1-GIP Dual Agonists

55. Indications for GLP-1 RAs in Patients With CVD Guidelines

56. Indications for GLP-1 RAs in Weight Management 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guidelines

57. Adding Incretin Therapy in Cardiology Care

58. Contraindications

59. Using GLP-1 RAs in Cardiology Care

60. Moving Towards Collaborative Care

61. Taking the Lead in Obesity Management in Cardiology

62. Cardiologists’ Role in Obesity Management in Their Patients

63. Starting GLP-1 RAs in Cardiology Care

64. Titration Schedule for GLP-1 RAs

65. Supporting Patients to Manage Anticipated Adverse Effects

66. Guidance When Starting a GLP-1 RA

67. Guidance When Starting a GLP-1 RA

68. Concomitant Use of Glucose-Lowering Medication

69. Monitoring

70. Whole-Person Approach to Obesity Care

71. Thank You